Eligibility for Melanoma Treatment in Cuba

Understanding Eligibility

Melanoma treatment eligibility in Cuba is determined through a comprehensive medical review of each patient's diagnosis, staging, molecular profile (BRAF status), prior treatments, and overall health. Cuba's oncology team evaluates each case individually to design the most appropriate treatment plan.

Medical Review Process

The medical review requires:

• Pathology reports — Biopsy confirming melanoma diagnosis with Breslow thickness, ulceration status, mitotic rate, and histological subtype. Surgical excision pathology reports if wide local excision has been performed. • BRAF mutation testing — Essential for treatment planning. BRAF V600 mutations are found in approximately 40-50% of melanomas and determine eligibility for targeted therapy (BRAF/MEK inhibitors). • Sentinel lymph node biopsy results — If performed, showing whether melanoma has spread to regional lymph nodes. • Staging imaging — CT scan of chest/abdomen/pelvis, MRI brain (melanoma has a predilection for brain metastases), PET-CT if available. • Prior treatment history — Complete record of prior surgeries, immunotherapy, targeted therapy, or chemotherapy with dates and response. • Blood work — Recent complete blood count, liver/kidney function, LDH (lactate dehydrogenase, a prognostic marker in melanoma). • General health assessment — Medical history including comorbidities, current medications, and overall physical status.

The oncology team reviews these documents to confirm staging, assess treatment options, and design an individualized treatment plan.

Who Benefits Most

Melanoma treatment in Cuba may be particularly valuable for:

• Patients seeking surgical treatment — Wide local excision, sentinel lymph node biopsy, and lymph node dissection performed by experienced surgical oncologists. • Patients seeking a second opinion — Independent review of diagnosis, staging, and treatment plan. • Patients seeking conventional treatment at competitive costs. • Patients interested in experimental immunotherapy — Where clinical trials may be available. • Patients from countries with limited oncology infrastructure.

The medical team provides an honest assessment of treatment options for each individual case, including whether conventional treatment, experimental approaches, or palliative care is most appropriate.

Preparing Your Medical Records

To begin the eligibility review:

• Biopsy/excision pathology reports (including Breslow thickness, ulceration, mitotic rate) • BRAF mutation testing results • Sentinel lymph node biopsy results (if performed) • Staging imaging on CD/DVD (CT, MRI brain, PET-CT) • Complete treatment history • Recent blood work including LDH • Current medication list

Documents should ideally be in Spanish or English. SMC Salud assists with translation. The review takes 5-10 business days, after which a treatment proposal with eligibility confirmation and transparent cost estimate is provided.